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Abstract
Background: Elevated cardiac troponin I (cTnI) is frequently observed in patients with severe sepsis and septic shock.
However, the mechanisms underlying cTnI release in these patients are still unknown. To date no data regarding
coagulation disturbances as a possible mechanism for cTnI release during sepsis are available.
Methodology/Principal Findings: Consecutive patients with systemic inflammatory response syndrome (SIRS), sepsis or
septic shock without evidence of an acute coronary syndrome were analyzed. Coagulation parameters (clotting time (CT),
clot formation time (CFT), maximum clot firmness (MCF), a-angle) were assessed in native whole blood samples, and using
specific activators to evaluate the extrinsic and intrinsic as well as the fibrin component of the coagulation pathway with the
use of rotational thrombelastometry (ROTEM). Thirty-eight patients were included and 22 (58%) were cTnI-positive.
Baseline characteristics between TnI-positive and -negative patients were similar. The CT, CFT, MCF and the a-angle were
similar between the groups with trends towards shorter CT in the extrinsic and fibrin activation.
Conclusions/Significance: We found no differences in coagulation parameters analyzed with rotational thrombelastometry
between cTnI-positive and -negative patients with SIRS, severe sepsis, and septic shock. These findings suggest that
pathophysiological mechanisms other than thrombus-associated myocardial damage might play a major role, including
reversible myocardial membrane leakage and/or cytokine mediated apoptosis in these patients.
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Introduction
Elevated concentrations of cardiac troponin I (cTnI) are
frequently observed in patients with severe sepsis and septic shock
even in the absence of an acute coronary syndrome (ACS) [1].
Elevated cardiac cTnI in this setting are associated with left
ventricular dysfunction [2] and adverse outcome [3]. The
mechanisms underlying cTnI release in patients with sepsis are
still unknown, and a number of hypotheses have been formulated
[4]. Pre-existing coronary artery disease (CAD) and demand
ischemia could account for cTnI release in sepsis. However, we
have shown that cTnI release can also occur in patients in whom
significant CAD has been excluded with sensitive methods [5].
The coagulation system is activated in critically ill patients and
disseminated intravascular coagulation frequently occurs. A
procoagulant state resulting in microvascular thrombi may
promote organ dysfunction in sepsis. There is ample evidence
from the literature that platelet properties such as reactivity and
receptor density are associated with an increased risk of troponin
release with reduced coronary perfusion [6–8]. Thus, one might
speculate that septic patients with increased troponin concentra-
tions might show evidence of increased platelet reactivity; in fact, it
has been shown that septic patients show increased platelet-
leukocyte interaction [9], which is found early in myocardial
infarction [10] and which is associated with an increased troponin
release in patients undergoing percutaneous coronary interven-
tion; interestingly, this increase can be inhibited with the use of a
GP IIb/IIIa inhibitor [11]. The aim of the present study was to
compare properties of ex vivo clot formation between cTnI-
positive and -negative patients with systemic inflammatory
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properties of clot formation in SIRS and septic patients with the
help of thrombelastometry.
Methods
Ethic Statement
All patients, or in case of unconsciousness, their closest relatives,
signed a written informed consent. The study was approved by the
ethics comittee of the Kanton St. Gallen, Switzerland.
Patients
Thirty-eight consecutive patients referred to our medical
intensive care unit and fulfilling criteria for severe sepsis, septic
shock or SIRS were studied. Definitions for sepsis, septic shock,
and SIRS correspond to the criteria of the consensus conference of
the American College of Chest Physician and Society of Critical
Care Medicine [12]. Patients with evidence of an ACS defined as
chest pain with either ST-elevation, depression (.1 mm) or T-
wave inversions were excluded, as well as patients with a history of
CAD or with a recent (,14 days) history of cardiac surgery. In
unconscious patients ST-T abnormalities as described above were
sufficient to assume an ACS.
Study Course
A 12-lead ECG was obtained at study inclusion and after 12
and 24 hours. The simplified Acute Physiology Score II (SAPS-II)
was used to describe/assess disease severity at study entry [13]. An
experienced cardiologist blinded to cTnI levels performed
transthoracic echocardiography to assess left ventricular ejection
fraction (LVEF), using the biplane Simpson formula [14] within
24 hours of study inclusion, and in case of hemodynamic
deterioration during the study period. Standard therapy such as
antimicrobial therapy, renal replacement therapy, mechanical
ventilation or hemodynamic support, was not influenced by the
study and was at the physicians’ discretion. Survival was assessed
28 days after study inclusion. In case of death, an autopsy was
performed when ever possible. To exclude flow-limiting CAD in
cTnI-positive survivors, dobutamine stress echocardiography was
performed according to standard procedures [15] within 4 months
after recovery.
Laboratory Analyses
Blood was obtained from a radial arterial line and cTnI was
measured at the time of study inclusion and after 12, 24, 48, 96,
192 and 288 hours and analyzed from the serum on a day by day
basis with a second-generation assay (Access AccuTnI Troponin I;
Beckman Coulter Inc; Fullerton, California). Two consecutive
cTnI values .0.5 mg/l were considered ‘‘cTnI-positive’’. In
addition, creatine phosphokinase (CK), CK-MB activity and C-
reactive protein (CRP) were assessed. Blood samples for
hemostasis analysis were taken at study inclusion, and after 12,
24 and 48 hours and analyzed using rotational thrombelastometry
(ROTEMH; Pentapharm GmbH; Munich, Germany). The
method and the parameters of thrombelastometry have been
described in detail previously [16]. Briefly, thrombelastometry
evaluates the clotting process in vitro by assessment of the
viscoelastic properties in whole blood that occur during clot
activation, clot formation and stabilization as well as clot lysis
(figure 1). Thrombelastometry is a reliable method to evaluate
perioperative hypercoagulability [17] and has been widely used to
monitor coagulation and specifically guide blood component
therapy in trauma patients [18], abdominal surgery [19] and more
widely in hepatic [20] and cardiac surgery [21], conditions where
coagulation disorders are frequent. For clarity the following
parameters measured at maximum cTnI-level are explained: the
Figure 1. Example of the rotational thrombelastometry analysis. Liquid whole blood transmits no amplitude on the rotational
thrombelastograph tracing. As blood clots start to form, fibers composed of fibrin and platelets produce increasing amplitude in the rotational
thrombelastograph tracing. Hypercoagulable blood would typically show a shorter CT and CFT with a higher MCF and a steeper a-angle. CT=clotting
time: time between starting the reaction and first detection of fibrin generation R thrombin formation, start of fibrin polymerisation; CFT=clot
formation: time from initiation of clotting until a defined clot strength can be first detected R fibrin polymerization, clot stabilization with
thrombocytes and F XIII; MCF=maximal firmness of the clot: maximum amplitude recorded, firmness of the clot R increasing clot stabilisation by
polymerized fibrin, thrombocytes and F XIII.
doi:10.1371/journal.pone.0009017.g001
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clot firmness (MCF) and the a-angle. The CT reflects the time
between starting the reaction and first detection of fibrin
generation. The CFT reflects the time until defined clot strength
is reached, representing clot generation by plasmatic and cellular
(platelets) components. The MCF corresponds to the maximum
amplitude recorded by the thrombelastograph, which is equivalent
to the maximum tensile strength of the whole clot. The a-angle
assesses the velocity of fibrin polymerization, thus the speed of clot
formation. Hypercoagulable blood would typically show a shorter
CT and CFT with a higher MCF and steeper a-angle.
All coagulation parameters were measured in whole blood
samples without addition of specific reagents (NATEM), and using
specific activators to evaluate the extrinsic (EXTEM) and intrinsic
(INTEM) pathway of the coagulation system. In addition, by
blocking platelets the fibrin component of the coagulation
(FIBTEM) was analyzed separately. Thus, through analysis of
whole blood samples, thrombelastometry assesses cellular and
plasmatic components simultaneously, allowing the plasmatic
coagulation system to interact with cellular components, and
therefore provides complete information during the process of clot
initiation, formation and stabilization [16].
Statistical Analysis
Categorical data are presented as numbers (percentages) and
continuous data as mean 6 standard deviation or median values
(interquartile ranges, IQR) as appropriate. Fisher’s exact test was
used to compare categorical variables, and Mann Whitney-U tests
were used to compare continuous data. A p-value ,0.05 was
considered statistically significant. Statistical calculations were
performed using the statistical package SPSS 16 for Mac (SPSS
Inc. USA).
Results
Demographic data of the thirty-eight included patients are
presented in table 1. Six patients (16%) were aplastic due to
chemotherapy for hematologic malignancies. The rate of intrave-
nous heparin treatment was similar in both groups and no patient
received other anticoagulant therapy or platelet transfusion during
the study period. The majority had severe sepsis (19%) or septic
shock (42%). None of the study patients had symptoms or clinical
signs of manifest CAD at study inclusion. However, non-specific
ST-segment alterations (,1 mm) were found in three (13%) cTnI-
positive, and in one (6%) cTnI-negative patient.
Median values of LVEF, laboratory parameters such as CRP,
creatinine, and CK, supportive therapy by means of mechanical
ventilation, renal replacement therapy, and the use of catechol-
amines did not differ between cTnI-positive and -negative patients.
In addition, disease severity indicated by SAPS-II at study
inclusion was similar in cTnI-positive and -negative patients
(table 2).
Clotting Parameters
No differences in the coagulation parameters CT, CFT, MCF
and the a-angle analyzed with the use of rotational thrombelas-
tometry were found between cTnI-positive and -negative patients.
In EXTEM and FIBTEM trends towards shorter CT were found
(table 3). Table 1. Baseline characteristics of the study population
(n=38).
Age (yrs) 66614
Male gender 19 (50%)
Body Mass Index (kg/m
2)2 7 65
SAPS-II (score points) 55623
Systemic inflammatory response syndrome 10 (26%)
Sepsis 5 (13%)
Severe sepsis 7 (19%)
Septic shock 16 (42%)
Main diagnosis
Pneumonia 14 (37%)
Cholezystitis/cholangitis 3 (8%)
Erysipelas 3 (8%)
Colitis 2 (5%)
Pancreatitis 1 (3%)
Peritonitis 2 (5%)
Meningitis 1 (3%)
Urosepsis 1 (3%)
Type of pathogen
Gram positive 15 (40%)
Gram negative 11 (29%)
Fungal infection 2 (5%)
Culture negative 10 (26%)
Data are presented as numbers (%) and mean 6 standard deviation as
appropriate. SAPS-II=simplified acute physiology score II (high scores indicate
severe illness).
doi:10.1371/journal.pone.0009017.t001
Table 2. Baseline characteristics other than coagulation
between cTnT+ and cTnT2 patients with SIRS or sepsis.
Covariates
cTnI+
(n=22)
cTnI2
(n=16) p value
Age (yrs) 65613 63613 0.77
Male gender 10 (46%) 9 (56%) 0.74
Body Mass Index (kg/m
2)2 9 672 7 66 0.39
Aplastic 2 (9%) 4 (25%) 0.18
Systolic blood pressure (mmHg) 104624 111617 0.31
Diastolic blood pressure (mmHg) 61615 5967 0.65
Heart rate (bpm) 102619 98617 0.58
SAPS-II (points) 55622 54626 0.89
Septic shock 8 (37%) 8 (50%) 0.50
Left ventricular ejection fraction (%) 58614 58612 0.98
Mechanical ventilation 14 (64%) 8 (50%) 0.51
Renal replacement therapy 10 (45%) 6 (38%) 0.74
C-reactive protein (mg/l, ,8.0) 3346121 3576135 0.57
Creatinine (mmol/l, m,115; f,95) 141 (101–245) 119 (96–160) 0.27
Creatinephosphokinase (U/l, ,170) 224 (78–1650) 151 (30–529) 0.16
Hemoglobin (g/l) 96620 93612 0.60
Troponin I (mg/l) 1.7 (0.8–4.6) 0.1 (0.07–0.3) 0.0001
Mortality 6 (27%) 4 (25%) 0.99
Data are presented as numbers (%) and mean 6 standard deviation or median
(IQR) as appropriate. SAPS-II=simplified acute physiology score II (high scores
indicate severe illness).
doi:10.1371/journal.pone.0009017.t002
Troponin Elevation in Sepsis
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9017Troponin Status and Flow Limiting CAD
Twenty-two (58%) of all study patients were cTnI-positive.
Median cTnI level in cTnI-positive patients was 1.7 mg/l (0.8–4.6).
Among the sixteen cTnI-positive survivors, significant flow limiting
CAD could be excluded by dobutamine stress-echocardiography
after recovery from disease inseven patients (44%), and by coronary
angiography in one patient (6%). In the remaining eight cTnI-
positive survivors, one had a normal coronary angiogram
performed one day before study inclusion, and in two patients a
recent (,6 months) non-invasive cardiac exercise testing (myocar-
dial perfusion scintigraphy in one patient and cycle ergometer
testing in another patient) did not reveal significant CAD. Thus, in
69% (11/16) of cTnI-positive survivors, significant CAD could be
ruled out. Ten patients of the entire study population (26%), 6/22
(27%) cTnI-positive and 4/16 (25%) cTnI-negative patients had
died. Autopsy was performed in seven patients; thereof four patients
(57%) were cTnI-positive. Of those three had normal coronary
arteries, and one patient had CAD with a thrombotic obstruction of
the left anterior descending artery and cardiomyocyte necrosis
representing an acute myocardial infarction. In three cTnI-negative
patients, no flow-limiting CAD was found at autopsy. Overall we
could exclude relevant CAD in 64% (14/22) of cTnI-positive
patients. Mortality assessed 28 days after study inclusion did not
differ between cTnI-positive and -negative patients.
Discussion
We hypothesized that cTnI elevation in SIRS and septic
patients might be a consequence of microvascular flow disturbance
provoked by a hypercoagulable state resulting in cardiomyocyte
damage or death. Therefore, we prospectively investigated clotting
parameters in 38 patients with SIRS and sepsis with the use of
rotational thrombelastometry. This is to our knowledge the first
study investigating the coagulation system in SIRS and septic
patients with respect to their cTnI-status. However, no differences
in clotting parameters as assessed by rotational thrombelastometry
between cTnI-positive and -negative patients were found.
Furthermore we ruled out relevant CAD as an alternative cause
for cTnI elevation in the majority of the cTnI-positive patients.
It has been shown that thrombelastographic variables reflect
additional information on the hemostatic process compared to
common coagulation laboratory parameters, such as fibrinogen or
activated partial thromboplastin time [22]. A recently published
study used thrombelastometry, plasmatic coagulation parameters
and platelet count to assess the coagulation system in septic
patients before and during a short-term antithrombin therapy.
The authors describe a hypercoagulable state in all septic patients
before treatment as assessed by thrombelastometry [23]. As the
coagulation status assessed with thrombelastometry is performed
in whole blood, this technique seems to mirror the overall
coagulation effects more closely than classical clotting parameters
or activation markers (e.g. thrombin-antithrombin complexes) as
all components of the blood - plasmatic, cellular components and
platelets - can contribute to clot formation. Thrombelastometry
detects a hypercoagulable state in patients who have experienced a
venous or arterial thrombotic event [24]. However, it has to be
kept in mind that thrombelastometry is relatively insensitive to
changes in the so-called ‘‘primary hemostasis’’ (e.g. platelet
dysfunction, von Willebrand disease etc.).
How can our findings be interpreted in context to previous
studies? Several decades ago Parillo et al. described a circulating
myocardial depressant substance in septic patients who showed
reversible depression of LVEF [25]. Later, it turned out that
Interleukin-6 (IL-6) and Interleukin-1b (IL-1b) play a major role in
left ventricular dysfunction in septic patients [26]. However, the
observation that severely impaired LVEF in septic patients most
often improves after disease recovery speaks against a major
myocardial cell death in septic patients. Interestingly, cytokine
mediated leakage of structural proteins such as troponins could be
demonstrated in vitro [27].
This hypothesis is supported by our previous clinical study in
septic patients showing significantly elevated tumor-necrosis-factor
a (TNFa) and IL-6 in troponin-positive as compared to -negative
patients [5]. However, thrombus-mediated microvessel occlusion,
as an underlying cause for troponin elevation in septic patients has
never been studied as a possible mechanism.
Limitations
The complexity of the human coagulation system is difficult to
assess by a single laboratory analysis, and other changes of the
coagulation system not detected by thrombelastometry might play
a role in this setting. As this is an exploratory study we cannot
exclude that other components of the coagulation system (that
were not evaluated in the current study) might be important with
regard to troponin positivity. Classical thrombelastography is
rather insensitive to platelet function. Despite the increased
robustness of the ROTEM assay, we cannot exclude that
ROTEM analysis assessed from arterial blood specimens is not
sensitive enough to detect minor coagulation differences in cardiac
microcirculation between troponin positive and negative patients.
The small sample size is a limitation to our study. We did not
explore the impact of disease severity (e.g. from SIRS to septic
shock) on the coagulation system between cTnI-positive and –
Table 3. Coagulation parameters.
cTnI+ cTnI2 p value
NATEM
CT 672 (564–990) 764 (602–1104) 0.50
CFT 182 (112–239) 138 (64–247) 0.44
MCF 57 (38–67) 57 (38–64) 0.74
a-angle 62 (43–70) 52 (41–66) 0.59
INTEM
CT 188 (177–217) 200 (192–228) 0.25
CFT 66 (50–143) 56 (50–78) 0.39
MCF 61 (46–70) 56 (47–69) 0.81
a-angle 76 (72–79) 78 (75–79) 0.62
EXTEM
CT 64 (55–71) 70 (62–79) 0.08
CFT 74 (57–158) 78 (61–101) 0.90
MCF 62 (51–69) 58 (46–70) 0.72
a-angle 75 (71–79) 76 (72–78) 0.62
FIBTEM
CT 64 (57–68) 70 (60–77) 0.09
CFT 90 (61–201) 87 (68–141) 0.53
MCF 30 (23–35) 34 (27–40) 0.13
a-angle 75 (69–77) 75 (72–76) 0.85
Data are presented as median (IQR). NATEM=native coagulation (without
addition of specific reagents); INTEM, EXTEM=intrinsic and extrinsic
coagulation pathway (specific activators are added); FIBTEM=fibrin component
of the coagulation (platelets are specifically blocked). See figure 1 for
abbreviations of the clotting parameters.
doi:10.1371/journal.pone.0009017.t003
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towards shorter CT times in EXTEM and FIBTEM, one could
speculate that the results may have been different had more
patients been included. However, we are aware of the difficulties
to assess the function of the coagulation system ‘‘ex vivo’’.
Conclusion
In a relatively small group of patients with SIRS, sepsis, and
septic shock we found no differences in coagulation parameters
analyzed with rotational thromboelastometry between cTnI-
positive and -negative patients. According to the results of the
present study, other mechanisms than thrombus-associated
myocardial damage might play a major role in cTnI-positive
patients with severe sepsis and septic shock. Clinical and
experimental studies suggest that cytokines, especially TNFa, IL-
1b and IL-6 appear to play a pivotal role in mediating the
hemodynamic effects and the release of cardiac troponin in
patients with severe sepsis and septic shock. Proposed mechanisms
are cytokine-mediated reversible myocardial membrane leakage
and/or apoptosis.
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